Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a.
The authors studied the tolerability of subcutaneous interferon beta-1a (IFNbeta-1a) in 51 patients with early-onset multiple sclerosis. The most frequent systemic adverse effects were flu-like symptoms in 65%. Laboratory abnormalities included asymptomatic leukopenia (27%) and elevated hepatic transaminases (35%). Treatment with IFNbeta-1a was safe and well tolerated in the majority of children and adolescents.
Pohl
Daniela
D
Department of Pediatrics and Pediatric Neurology, Georg-August-University Goettingen, Robert-Koch-Strasse 40, 37075 Germany. E-mail: dpohl@med.uni-goettingen.de.
Rostasy
Kevin
K
Gärtner
Jutta
J
Hanefeld
Folker
F
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects; D000293:Adolescent; D017668:Age of Onset; D002490:Central Nervous System / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D002648:Child; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000008:administration & dosage* / Q000009:adverse effects; D007970:Leukopenia / Q000139:chemically induced / Q000276:immunology; D008099:Liver / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000503:physiopathology; D012189:Retrospective Studies; D055502:Secondary Prevention; D000637:Transaminases / Q000187:drug effects / Q000378:metabolism; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D016899:Interferon-beta; D000637:Transaminases; D000068556:Interferon beta-1a